KDR and nasopharyngeal carcinoma: ZD6474 is a novel VEGFR-2, EGFR and Src tyrosine kinase inhibitor, which suppresses a number of tumors, including non-small cell lung cancer as well as breast, gastric, prostate, colorectal, nasopharyngeal cancers and leukemia, through inhibiting tumor cell growth and survival [31-34].